Combined treatment of androgen-independent prostate cancer cell line DU145 with chemotherapeutic agents and lithium chloride: Effect on growth arrest and/or apoptosis

Avicenna Journal of Medical Biotechnology

Volumn 4, Issue 2, 2012, Pages 75-87

  Hossein, Ghamartaj ^a   Zavareh, Vajihe Azimian ^a,b   Fard, Parissa Sahranavard ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

^b ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

Author keywords

Antineoplastic agents; Combination therapy; GSK 3 ; Lithium chloride; p53

Indexed keywords

DOXORUBICIN; ETOPOSIDE; LITHIUM CHLORIDE; PROTEIN P53; VINBLASTINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DU145 CELL; HUMAN; HUMAN CELL; IC 50; PROSTATE CANCER;

EID: 84862024493     PISSN: 20082835     EISSN: 20084625     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. van Brussel JP, van Steenbrugge GJ, Romijn JC, Schröder FH, Mickisch GH. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 1999; 35(4):664-671.
2. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 2004;145(6):2941-2949.
3. Mazor M, Kawano Y, Zhu H, Waxman J, Kypta RM. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 2004;23(47):7882-7892.
4. Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear betacatenin accumulation. J Biol Chem 2002;277(34): 30935-30941.
5. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, et al. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 2004;279(18):19191-19200.
6. Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C. Suppression of androgen receptor mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem 2004; 279(31): 32444-32452.
7. Cronauer MV, Schulz WA, Ackermann R, Burchardt M. Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol 2005;26(4):1033-1040.
8. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1): 33-39.
9. Liao X, Zhang L, Thrasher JB, Du J, Li B. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2003;2(11):1215-1222.
10. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000;406(6791):86-90.
11. Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D. DU145 and PC-3 human prostate cell lines express androgen receptor: Implications for the androgen receptor functions and regulation. FEBS Letters 2006;580(9): 2294-2300.
12. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko S P, Pavloff N, et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57(9):1758-1768.
13. Bajgelman MC, Strauss BE. The DU145 human prostate carcinoma cell line harbors a temperaturesensitive allele of p53. Prostate 2006;66(13):1455-1462.
14. Sun A, Shanmugam I, Song J, Terranova PF, Thrasher JB, Li B. Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate 2007;67(9):976-988.
15. Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB, et al. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate 2011;1(8):835-845.
16. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, et al. A randomized Phase II trial of docetaxel (taxotere) plus thalidomide in androgenindependent prostate cancer. Semin Oncol 2001;28 (4 Suppl 15):62-66.
17. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 2008; 6:e001.
18. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 2007;6 (10):2696-2707.
19. Dorr RT, Von-Hoff DD. Drug Monographs. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, Connecticut: Appleton and Lange; 1994.
20. Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB, et al. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res 2003;63(11):2905-2912.
21. Brady CA, Attardi LD. p53 at a glance. J Cell Sci 2010;123(pt 15):2527-2532.
22. Mao CD, Hoang P, DiCorleto PE. Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells. J Biol Chem 2001;276(28):26180-26188.
23. Javanmard SH, Nematbakhsh M, Mahmoodi F, Mohajeri MR. l-Arginine supplementation enhances eNOS expression in experimental model of hypercholesterolemic rabbits aorta. Pathophysiology 2009;16(1):9-13.
24. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71(3 Suppl):1098-1109.
25. Cohen MB, Rokhlin OW. Mechanisms of prostate cancer cell survival after inhibition of AR expression. J Cell Biochem 2009;106(3):363-371.
26. Ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. Structure of GSK3beta reveals a primed phosphorylation mechanism. Nature Struct Biol 2001;8(7):593-596.
27. Li R, Erdamar S, Dai H, Sayeeduddin M, Frolov A, Wheeler TM, et al. Cytoplasmic accumulation of glycogen synthase kinase-3β is associated with aggressive clinicopathological features in human prostate cancer. Anticancer Res 2009;29(6):2077-2081.
28. Rinnab L, Schutz SV, Diesch J, Schmid E, Kufer R, Hautmann RE, et al. Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: Are GSK inhibitors therapeutically useful? Neoplasia 2008;10(6):624-634.
29. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, et al. Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 2001;1(2):113-130.
30. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56(2):185-229.
31. Schotte P, Van Loo G, Carpentier I, Vandenabeele P, Beyaert R. Lithium sensitizes tumor cells in an NF-κβ-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF). Evidence for a role of the TNF receptor-associated death domain protein. J Biol Chem 2001;276(28): 25939-25945.
32. Beyaert R, Heyninck K, De Valck D, Boeykens F, van Roy F, Fiers W. Enhancement of tumor necrosis factor cytotoxicity by lithium chloride is associated with increased inositol phosphate accumulation. J Immunol 1993;151(1):291-300.
33. Munshi A, Pappas G, Honda T, McDonnell TJ, Younes A, Li Y, et al. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Oncogene 2001;20(29):3757-3765.
34. Srivastava RK. TRAIL/Apo-2L: Mechanisms and clinical applications in cancer. Neoplasia 2001;3 (6):535-546.
35. Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, et al. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate 2006;66(9):987-995.
36. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 1999;59(11):2551-2556.
37. Cohen Y, Chetrit A, Cohen Y, Sirota P, Modan B. Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med Oncol 1998; 15(1):32-36.
38. Ballin A, Aladjem M, Banyash M, Boichis H, Barzilay Z, Gal R et al. The effect of lithium chloride on tumour appearance and survival of melanomabearing mice. Br J Cancer 1983;48(1):83-87.